<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472523</url>
  </required_header>
  <id_info>
    <org_study_id>07H0607101</org_study_id>
    <nct_id>NCT01472523</nct_id>
  </id_info>
  <brief_title>A Safer Pre-Natal Diagnosis Using Free DNA in Maternal Blood</brief_title>
  <acronym>IONA</acronym>
  <official_title>A Safer Pre-Natal Diagnosis Using Free DNA in Maternal Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Premaitha Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Premaitha Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A diagnostic peripheral maternal blood test taken and the free foetal DNA is analysed and the&#xD;
      presence of trisomies using a novel method.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of ~2000 participants have donated blood samples used for the development and&#xD;
      validation of the IONA non-invasive prenatal screening test for Downs, Edwards and Patau&#xD;
      syndrome. The IONA Test was CE marked Feb 2013. We are now recruiting a further 800&#xD;
      participants to provide blood samples to further develop and verify the test for other&#xD;
      chromosomal abnormalities and to improve test efficiency.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of method of novel analysis for Aneuploidy</measure>
    <time_frame>2013 Approx</time_frame>
    <description>Analysis of maternal blood by a selective amplification of fetal DNA over maternal DNA within that sample. Patients to be followed up for 1 year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimization of existing methods for maximising ffDNA</measure>
    <time_frame>up to July 2019</time_frame>
    <description>Use of novel methods either in conjugation with existing methods or as a substitute for steps in existing methodologies- currently undergoing laboratory development that could increase the titre of fetal DNA within a given sample. Patients will be followed up for 1 year.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1632</enrollment>
  <condition>Aneuploidy, NIPT</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Aneuploidy</arm_group_label>
    <description>T13, 18, 21 and other chromosomal abnormalities yet to be determined</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal peripheral blood samples taken in EDTA with that required for existing analysis.&#xD;
&#xD;
      Approx 1ml of fluid from amniocentesis/chorionic villus sampling is taken additional.&#xD;
      Patients will be followed up for 1 year after sample taken.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Mothers attending clinic for routine screening. Followed up at around 1 years duration.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient/subject is willing and able to give informed consent for participation in the&#xD;
             study.&#xD;
&#xD;
          -  Female, aged 16 years or above.&#xD;
&#xD;
          -  Currently pregnant at time of entry to the study.&#xD;
&#xD;
          -  Pregnancy having been identified as 'high-risk' by screening test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient/subject may not enter the study if ANY of the following apply:&#xD;
&#xD;
          -  The participant herself has Down's Syndrome or other chromosomal abnormality.&#xD;
&#xD;
          -  Children under 16&#xD;
&#xD;
          -  Adults with learning disabilities&#xD;
&#xD;
          -  Adults who are unconscious or very severely ill&#xD;
&#xD;
          -  Adults who have a terminal illness&#xD;
&#xD;
          -  Adults in emergency situations&#xD;
&#xD;
          -  Adults suffering from a mental illness&#xD;
&#xD;
          -  Adults with dementia&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Young offenders&#xD;
&#xD;
          -  Adults who are unable to consent for themselves&#xD;
&#xD;
          -  Any person considered to have a particularly dependent relationship with investigators&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Kelly, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health Service, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premaitha Health</name>
      <address>
        <city>Manchester</city>
        <zip>M156SZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>November 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneuploidy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

